Artificial intelligence (AI) is transforming how life sciences organizations approach drug development, diagnostics, personalized care and more. Now, many are exploring how AI can enhance patient support programs (PSPs) by improving efficiency, patient and healthcare provider experiences and improved outcomes.
In this Drug Channels Institute article, Chief Product Officer William Grambley explores how AI is being applied in PSPs, key considerations for responsible implementation, and how to evaluate the right use cases for your organization’s goals.
Drug Channels Institute is one of the industry’s leading publications offering expert insights on pharmaceutical economics and the drug distribution systems.